Skip to main content
Premium Trial:

Request an Annual Quote

Ferrer to Sell Agendia's Cancer Dx Services

NEW YORK (GenomeWeb News) – Ferrer inCode, the biotech subsidiary of Spanish firm Grupo Ferrer, has gained exclusive rights to sell two of Agendia’s cancer diagnostic services in certain European countries, the firms said today.
 
Ferrer will offer Agendia’s MammaPrint and CupPrint tests in Germany, France, Italy, and Portugal. Ferrer already sells the tests in Spain under an agreement signed last year.
 
MammaPrint is a prognostic, gene expression profiling test that uses 70-gene signature to indicate the risk of breast cancer tumor recurrence. CupPrint is a gene expression profiling service that is used to identify the primary tumor site in cancer of unknown primary.
 
The firms said that they are discussing a potentially expanded deal to include other parts of the world.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.